Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01825577 · ClinicalTrials.gov registry record · Phase 4
Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.
A Phase 4 study, sponsored by St. Louis University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT01825577 is a Phase 4 study that was terminated before completion, run by St. Louis University. The registered enrollment target is 14 participants.
The verdict
NCT01825577, a Phase 4 study, was terminated before completion, sponsored by St. Louis University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
Falls in the elderly are a very common and serious health problem with devastating consequences. Those with dementia are 5 times more likely to experience falls than older people without significant cognitive impairment. Despite a growing awareness and the use of available treatments, the number of falls and fall related injuries continue to increase. It is important to develop more effective treatments to help reduce the number of falls and prevent injury. The assessments used in this study determine fall risk which predicts the likelihood of falls in the future. This study will evaluate the possible role of Methylphenidate, Ritalin, in preventing falls and improving symptoms of apathy, or indifference. Methylphenidate is FDA approved for the treatment of ADHD but is not currently approved by the FDA for preventing falls or improving apathy(lack of interest) in the elderly. The methylphenidate used in this study will be absorbed through the skin by wearing a small patch near the hip area. The specific primary aim of this open label study is to determine if use of transdermal Methylphenidate (t-MPH) causes a reduction in fall risk in patients with dementia. The hypotheses to be tested is that after receiving t-MPH for 4 weeks, subjects will show improvement in gait and mobility assessment scores when compared to gait and mobility scores at screening.
Interventions
- DRUG Transdermal Methylphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01825577
The ClinicalTrials.gov registry entry for NCT01825577 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Louis University, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Transdermal Methylphenidate is the first listed.
NCT01825577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01825577 about?
NCT01825577 is a clinical study titled "Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.". Falls in the elderly are a very common and serious health problem with devastating consequences. Those with dementia are 5 times more likely to experience falls than older people without significant cognitive impairment. Despite a growing awareness and the use of available treatments, the number of ...
What is the current status of trial NCT01825577?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2012-11. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01825577?
The interventions under investigation include: Transdermal Methylphenidate (DRUG).
Who is sponsoring clinical trial NCT01825577?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.